Continuing Medical Education Programs

FDA Approves Ipilimumab for the Treatment of Unresectable or Metastatic Melanoma: A Review of Its Benefits and Risks CME/CE

Jeffrey S. Weber, MD, PhD; Emma Hitt, PhD

CME/CE Released: 03/31/2011; Valid for credit through 03/31/2012

This activity is intended for oncologists, dermatologists, endocrinologists, emergency medicine physicians, gastroenterologists, neurologists, radiologists, surgeons, and pharmacists as well as other healthcare professionals who treat patients with melanoma.

The goal of this activity is to review the benefits and risks of ipilimumab therapy.

Upon completion of this activity, participants will be able to:

  1. Discuss the benefits and risks of ipilimumab therapy in patients with unresectable or metastatic melanoma
  2. Formulate treatment plans for patients with unresectable or metastatic melanoma based on current clinical trial data
  3. Assess signs and symptoms of potential adverse reactions related to ipilimumab and implement appropriate management strategies

———————————–

Metastatic Melanoma – Immunotherapy
Author(s)/Faculty: Omid Hamid, MD; Stephen Hodi, MD; Douglas Schwartzentruber, MD, FACS
Source: HemOnc Today Type: Multimedia Articles/Items: 4
Release Date: 8/25/2011 Expiration Date: 8/24/2012 Cost: Free
Credit Type: CME Number of Credit(s): 2.75 Provider:
OVERVIEW

Melanoma, the fifth most common cancer and the deadliest form of skin cancer, is diagnosed in 68,130 patients and claims 8,700 individuals per year. Although it can be curable if caught early, treatment options are limited for patients with advanced disease, and prognosis is poor. Earlier detection, appropriate staging, individualized treatment, and the use of new therapies, when they become available, are the most promising options for improving patient prognosis and relieving the growing public health burden of melanoma. In this activity, leading clinicians will offer practical recommendations based on the state of the science and recent clinical trials that can be employed immediately to improve outcomes for patients with melanoma.

———————————–

From Medscape Education Clinical Briefs

Calcium Plus Vitamin D Intake Ineffective in Reducing Skin Cancer Risk CME

Was Dose Adequate?

News Author: Nick Mulcahy
CME Author: Laurie Barclay, MD

CME Released: 07/06/2011; Valid for credit through 07/06/2012

———————————–

From Medscape Education Clinical Briefs

Age, Family History Affect Early Detection of Melanoma CME

News Author: Laurie Barclay, MD
CME Author: Charles P. Vega, MD

CME Released: 06/24/2011; Valid for credit through 06/24/2012

———————————–

FDA Approves Ipilimumab for the Treatment of Unresectable or Metastatic Melanoma: A Review of Its Benefits and Risks CME/CE

Jeffrey S. Weber, MD, PhD; Emma Hitt, PhD

This activity is intended for oncologists, dermatologists, endocrinologists, emergency medicine physicians, gastroenterologists, neurologists, radiologists, surgeons, and pharmacists as well as other healthcare professionals who treat patients with melanoma.

CME/CE Released: 03/31/2011; Valid for credit through 03/31/2012

——————————————————————————————————————

Dermoscopy of Nevi and Melanoma in Childhood

Christine Brooks, BS; Alon Scope, MD; Ralph Braun, MD; Ashfaq A. Marghoob, MD

CME Released: 02/07/2011; Valid for credit through 02/07/2012


———————————–

Comments are closed.